Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
暂无分享,去创建一个
[1] C. Paiva,et al. LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer , 2016, World Journal of Urology.
[2] H. Payne,et al. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK , 2016, World Journal of Urology.
[3] K. Moretti,et al. Men presenting with prostate‐specific antigen (PSA) values of over 100 ng/mL , 2016, BJU international.
[4] E. Crawford,et al. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl , 2015, Expert opinion on drug metabolism & toxicology.
[5] F. Saad,et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[6] N. Corcoran,et al. Adverse effects of androgen‐deprivation therapy in prostate cancer and their management , 2015, BJU international.
[7] D. Dearnaley,et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] W. Lowrance,et al. Castration‐Resistant Prostate Cancer: AUA Guideline Amendment 2018 , 2015, The Journal of urology.
[9] D. Perry-Keene. Low testosterone in men , 2014 .
[10] E. Crawford,et al. Maximal testosterone suppression in prostate cancer--free vs total testosterone. , 2014, Urology.
[11] B. Shayegan,et al. Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[12] A. Geldof,et al. Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer , 2013, World Journal of Urology.
[13] W. J. Morris,et al. Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter? , 2012, BJU international.
[14] L. Klotz,et al. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? , 2012, Current oncology.
[15] L. Reis,et al. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer , 2012, International Urology and Nephrology.
[16] T. H. van der Kwast,et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.
[17] V. Ficarra,et al. Impact of Surgical and Medical Castration on Serum Testosterone Level in Prostate Cancer Patients , 2009, Urologia Internationalis.
[18] J. Morote,et al. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy , 2009, BJU international.
[19] M. Miner,et al. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. , 2007, Cleveland Clinic journal of medicine.
[20] M. Resnick,et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. , 2000, Urology.
[21] C. Huggins,et al. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.
[22] W. Lowrance,et al. Castration-resistant prostate cancer: AUA guideline amendment. , 2015, The Journal of urology.
[23] Thomas Wiegel,et al. Guidelines on Prostate Cancer , 2013 .
[24] T. H. van der Kwast,et al. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. , 2011, Actas urologicas espanolas.
[25] L. Gomella. Effective testosterone suppression for prostate cancer: is there a best castration therapy? , 2009, Reviews in urology.